Compare Books

You have no items to compare.

Recently Viewed

Advanced Tax Strategies for LLCs and Partnerships

Home >
Law >
Medical Law >
Competition Law and IP Rights in the Pharmaceuticals and Biotechnology Sectors

Coming Soon Competition Law and IP Rights in the Pharmaceuticals and Biotechnology Sectors

Competition Law and IP Rights in the Pharmaceuticals and Biotechnology Sectors

Author: Bjorn Lundqvist; Timo Minssen; Justin Pierce
Publisher: Oxford University Press
ISBN: 9780198724827
Published In: August 2031
Format: Hardback
Jurisdiction: U.K. ? Disclaimer:
Countri(es) stated herein are used as reference only

List Price: HKD 1,885.00

HKD 1,828.45 Save HKD 56.55 (3%)

Download Order Form

Add to Wishlist
| Add to Compare

Description
Contents

Details

This book provides an analytical overview of the function and application of competition law and intellectual property (IP) law in the pharmaceutical and biotechnology sectors. It offers a general introduction to the foundations and principles of competition law and its interface with intellectual property law, as well as a brief scientific preface, and an overview of the competitive environment and innovation system in which the pharmaceutical industry operates. It presents and discusses practices and conduct that have been identified as allegedly anticompetitive, analysing them from the perspectives of both competition and intellectual property law.

The book discusses the issues raised by the 2009 EU (European Union) Pharmaceutical Sector Inquiry in depth, with reference to the case law that has developed since the Inquiry was published. In particular, the book scrutinises the cases and investigations in the European Union and United States regarding 'pay-for-delay' and other settlement agreements, the misuse of the patent systems, the misuse of the courts, and the alleged misuse of the regulatory system by pharmaceutical companies. It considers co-marketing, co-promotion, and co-branding from an antitrust perspective. There is discussion of different patent strategies and whether they violate competition law or patent law.

The book also covers the introduction of the unitary patent in Europe, the Unified Patent Court, and their implications for the utilization of competition law. The book describes and explains developments relating to competition law and intellectual property law in the relevant sectors, putting them into context from both a theoretical and practical perspective. It addresses important competition law issues that arise where IP rights are acquired and utilised in Europe. It also contains useful guidance on how to deal with competition issues that arise within the intellectual property framework, and discusses when competition law is applicable and when exemption under intellectual property law may be applied.

This comprehensive and detailed analysis is invaluable to practitioners, researchers, and students alike.

Part I: The Pharma and Biotech Business, Framework and Limitations

1: The Context, Purpose and Limitation of the Book

2: The Pharma Industry and its Business Strategies

3: The Legal Framework, Concepts and Basic Principles and the Parallel Trade Regulation

Part II: The Function of Competition Law

4: Pharma Agreements under Article 101 TFEU

5: Dominance and Abuse

6: Pharma Sector-Specific Abusive Conduct

7: A short comparative analysis of the development under EU Competition law with the US development under the antitrust laws, i.e. Secs.

1 and 2 Sherman Act and Sec.

5 FTC Act.

Part III: Solutions and Reflections

8: Competition within IPRs the solution to the problems now addressed under Competition law? - The way forward: Future developments, emerging issues and conclusions